Avexa Limited  

(Public, ASX:AVX)   Watch this stock  
Find more results for Mitchell M. Cox�
+0.0010 (6.67%)
Nov 26 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.02 - 0.02
52 week 0.01 - 0.03
Open 0.02
Vol / Avg. 30,000.00/3.06M
Mkt cap 14.81M
P/E     -
Div/yield     -
EPS 0.00
Shares 925.65M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin -429.15% -948.81%
Operating margin -402.03% -836.61%
EBITD margin - -796.27%
Return on average assets -19.85% -21.58%
Return on average equity -20.58% -22.38%
Employees 5 -
CDP Score - -


Suite 8, Level 1 61-63 Camberwell Road Hawthorn East
+61-3-88881040 (Phone)
+61-3-88881049 (Fax)

Website links


Avexa Limited is an Australia-based biotechnology company with a focus on research and development of anti-infectives. The Company is developing drugs for the treatment of infectious diseases. During the fiscal year ended June 30, 2012 (fiscal 2012), the Company was engaged in anti-infective pharmaceutical programs and projects. The Company operates in two segments: Research and Development, engaged in operation of conducting anti-infective research and development, and Listed investments, engaged in investing in the share market. The Company�s principal research programs focus on the discovery of medicines for the treatment of the diseases caused by human immunodeficiency virus (HIV) and vancomycin and methicillin-resistant bacteria. Apricitabine (ATC) is the Company�s nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection. HIV is the virus which causes acquired immunodeficiency syndrome (AIDS).

Officers and directors

Jonathan Coates Interim Chief Executive Officer, Chief Scientific Officer
M. Klapakis Financial Controller
Susan W. Cox Head of Drug Development
Lee Mitchell Company Secretary
Iain M.C. Kirkwood CPA Independent Non-Executive Chairman of the Board
Age: 61
Bruce Hewett Independent Non-Executive Director
Age: 59
Allan Tan Independent Non-Executive Director
Age: 48